Peptide Trainings

Thymosin Alpha-1 vs BPC-157

Compare immune-signaling and tissue-repair research.

Thymosin Alpha-1

A thymus-derived peptide for immune modulation and antiviral defense

Thymosin Alpha-1 is a peptide your thymus gland naturally produces to train and activate your immune cells. The thymus is the organ responsible for producing T-cells — the soldiers of your immune system. As we age, the thymus shrinks and produces fewer of these cells, which is one reason older people get sick more easily. Thymosin Alpha-1 is approved in over 35 countries as a medical treatment for hepatitis and immune deficiency, making it one of the most clinically validated peptides on this site.

Mechanism of action

Thymosin Alpha-1 works by helping immature immune cells in the thymus grow into fully functional T-cells. It also signals the immune system to produce more of its own communication chemicals (cytokines), which coordinate the immune response. Additionally, it activates natural killer cells — specialized immune cells that identify and destroy viruses and abnormal cells. The overall effect is a more capable, better-coordinated immune system.

Benefits discussed in research

  • Modulates and strengthens immune function
  • Antiviral and antibacterial properties
  • Enhances T-cell production and activity
  • Reduces chronic inflammation
  • Approved for hepatitis B and C treatment in some countries
  • May improve outcomes in sepsis

Research status

FDA Approved

Dosing information

For educational and research purposes only. Not medical advice.

typical
1.6 mg twice per week
range
0.8–3.2 mg per dose
frequency
Twice weekly
route
Subcutaneous injection
cycleLength
6–12 months for chronic conditions
notes
Approved dose in countries where it is licensed is 1.6 mg twice weekly. For general immune support, shorter cycles are used.

Side effects and safety

  • Injection site reactions
  • Mild flu-like symptoms initially
  • Generally very well tolerated

Frequently asked questions

Is Thymosin Alpha-1 approved in the US?

Not in the US — the FDA has not approved it here. But it is approved in over 35 other countries, including for treating hepatitis B, hepatitis C, and supporting cancer patients during treatment. In the US it is available as a research compound through compounding pharmacies.

Research references

Read the Thymosin Alpha-1 profile

BPC-157

The most studied healing peptide for tissue repair and gut health

BPC-157 is one of the most talked-about healing peptides in research circles. It is a short chain of amino acids (the building blocks of proteins) that was originally discovered in human stomach fluid. Your body already makes something like it naturally. The synthetic version has been studied extensively for its ability to speed up healing in muscles, tendons, ligaments, and the gut — often dramatically faster than normal recovery times.

Mechanism of action

BPC-157 works by sending signals that tell your body to build new blood vessels to an injured area (think of it like calling in extra supply lines to a construction site). More blood flow means more nutrients and repair cells reach the injury faster. It also boosts collagen production, which is the main structural protein in tendons, ligaments, and skin. On top of that, it has calming effects on the nervous system, which may explain why many users report reduced pain alongside faster healing.

Benefits discussed in research

  • Accelerates healing of tendons, ligaments, and muscles
  • Supports gut health and treats leaky gut syndrome
  • Reduces systemic inflammation
  • Promotes angiogenesis (new blood vessel formation)
  • Neuroprotective effects on the brain
  • May reduce pain associated with injuries

Research status

Preclinical

Dosing information

For educational and research purposes only. Not medical advice.

typical
500 mcg–1 mg once daily
range
500 mcg–2 mg/day
frequency
Once daily
route
Subcutaneous injection near the injury site, stomach, or upper arms
cycleLength
4–12 weeks
notes
For localized injuries, inject as close to the injury site as possible for the best effect. For gut health, injecting in the stomach area works well. Dose adjustments may be made based on individual response and clinical guidance.

Reconstitution and storage

Remove the caps from the bacteriostatic water (BAC water) and BPC-157 vial and clean both stoppers with alcohol swabs. Draw 200 units (2 mL) of bacteriostatic water into a syringe and inject it slowly into the BPC-157 vial. Gently swirl until fully dissolved — do not shake. The solution is now 5 mg/mL.

Lyophilized powder: store in a cool, dry place. Once reconstituted: refrigerate and use within 45–60 days.

Side effects and safety

  • Nausea (rare, usually mild)
  • Dizziness (rare)
  • Injection site irritation
  • Potential interaction with anticoagulants

Frequently asked questions

Is BPC-157 legal?

BPC-157 is not FDA approved for human use and is classified as a research compound. It is legal to purchase for research purposes in the US but should only be used under medical supervision.

Can I take BPC-157 orally?

Yes, oral BPC-157 is effective for gut-related issues. For systemic or localized injury healing, subcutaneous injection is more effective due to higher bioavailability.

How long until I see results?

Many users report noticeable improvements in injury recovery within 2–4 weeks. Gut health improvements can be noticed within days to a week.

How do I reconstitute a 10 mg BPC-157 vial?

Add 2 mL (200 units) of bacteriostatic water to the 10 mg vial. This gives a concentration of 5 mg/mL. For a 500 mcg dose draw 10 units; for a 1 mg dose draw 20 units; for a 2 mg dose draw 40 units on a U-100 insulin syringe.

Research references

Read the BPC-157 profile

More comparisons